Cargando…
Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects
This cross-sectional clinic-based study assessed and compared lipid profile, presence of metabolic syndrome (MetS), and liver enzymes in subjects with IGT, new onset treatment naïve T2DM, and normal glucose tolerance (NGT). INTRODUCTION: Type 2 diabetes (T2D) and IGT patients have increased dyslipid...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603104/ https://www.ncbi.nlm.nih.gov/pubmed/23565456 http://dx.doi.org/10.4103/2230-8210.104121 |
_version_ | 1782263634156584960 |
---|---|
author | Sanyal, Debmalaya Ghosh, Sujoy Mukherjee, Pradip Mukherjee, Satinath Chowdhury, Subhankar |
author_facet | Sanyal, Debmalaya Ghosh, Sujoy Mukherjee, Pradip Mukherjee, Satinath Chowdhury, Subhankar |
author_sort | Sanyal, Debmalaya |
collection | PubMed |
description | This cross-sectional clinic-based study assessed and compared lipid profile, presence of metabolic syndrome (MetS), and liver enzymes in subjects with IGT, new onset treatment naïve T2DM, and normal glucose tolerance (NGT). INTRODUCTION: Type 2 diabetes (T2D) and IGT patients have increased dyslipidemia, MetS, and alterations in liver enzymes. AIMS AND OBJECTIVES: To assess and compare lipid profile, presence of MetS, and liver enzymes in subjects with IGT, new onset treatment naïve T2DM, and NGT. MATERIALS AND METHODS: This cross-sectional clinic-based study examined 152 IGT and 158 recently detected T2D subjects aged between 30 and 69 years, never treated with any anti-hyperglycemic, anti-hypertensive, and lipid lowering drugs. One hundred and sixty age- and gender-matched controls with NGT were also selected. Anthropometry, lipid profile, dyslipidemia (ADA criteria), presence of MetS (NCEP, IDF), liver enzymes, insulin resistance (HOMA-IR and QUICKI), and β-cell function (HOMA β) were analyzed in all subjects. RESULTS: T2D and IGT subjects had significantly higher BMI, waist circumference, blood pressure (BP), HOMA-IR, QUICKI, fasting insulin, HOMA-β, MetS, triglyceride, LDL-C, SGPT, GGT, and lower HDL-C compared to NGT (control). High LDL-C (>100 mg/dl) was the commonest dyslipidemia followed by low HDL-C and hypertriglyceridemia in IGT and T2D. We found no significant differences in BMI, waist circumference, insulin resistance, total/LDL-C/HDL-C, and presence of MetS between T2D and IGT subjects. Diabetics exhibited significantly higher BP, triglyceride, SGPT, GGT, lower fasting insulin, and HOMA-β-cell function compared to IGT. CONCLUSIONS: IGT and recent onset T2D individuals had similar increased cardiovascular risk markers, liver enzymes, and prevalence of MetS. High LDL-C was the commonest dyslipidemia in IGT and T2D. T2D subjects had higher triglyceride, BP, SGPT, GGT compared to IGT. |
format | Online Article Text |
id | pubmed-3603104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-36031042013-04-05 Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects Sanyal, Debmalaya Ghosh, Sujoy Mukherjee, Pradip Mukherjee, Satinath Chowdhury, Subhankar Indian J Endocrinol Metab Brief Communication This cross-sectional clinic-based study assessed and compared lipid profile, presence of metabolic syndrome (MetS), and liver enzymes in subjects with IGT, new onset treatment naïve T2DM, and normal glucose tolerance (NGT). INTRODUCTION: Type 2 diabetes (T2D) and IGT patients have increased dyslipidemia, MetS, and alterations in liver enzymes. AIMS AND OBJECTIVES: To assess and compare lipid profile, presence of MetS, and liver enzymes in subjects with IGT, new onset treatment naïve T2DM, and NGT. MATERIALS AND METHODS: This cross-sectional clinic-based study examined 152 IGT and 158 recently detected T2D subjects aged between 30 and 69 years, never treated with any anti-hyperglycemic, anti-hypertensive, and lipid lowering drugs. One hundred and sixty age- and gender-matched controls with NGT were also selected. Anthropometry, lipid profile, dyslipidemia (ADA criteria), presence of MetS (NCEP, IDF), liver enzymes, insulin resistance (HOMA-IR and QUICKI), and β-cell function (HOMA β) were analyzed in all subjects. RESULTS: T2D and IGT subjects had significantly higher BMI, waist circumference, blood pressure (BP), HOMA-IR, QUICKI, fasting insulin, HOMA-β, MetS, triglyceride, LDL-C, SGPT, GGT, and lower HDL-C compared to NGT (control). High LDL-C (>100 mg/dl) was the commonest dyslipidemia followed by low HDL-C and hypertriglyceridemia in IGT and T2D. We found no significant differences in BMI, waist circumference, insulin resistance, total/LDL-C/HDL-C, and presence of MetS between T2D and IGT subjects. Diabetics exhibited significantly higher BP, triglyceride, SGPT, GGT, lower fasting insulin, and HOMA-β-cell function compared to IGT. CONCLUSIONS: IGT and recent onset T2D individuals had similar increased cardiovascular risk markers, liver enzymes, and prevalence of MetS. High LDL-C was the commonest dyslipidemia in IGT and T2D. T2D subjects had higher triglyceride, BP, SGPT, GGT compared to IGT. Medknow Publications & Media Pvt Ltd 2012-12 /pmc/articles/PMC3603104/ /pubmed/23565456 http://dx.doi.org/10.4103/2230-8210.104121 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Communication Sanyal, Debmalaya Ghosh, Sujoy Mukherjee, Pradip Mukherjee, Satinath Chowdhury, Subhankar Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects |
title | Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects |
title_full | Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects |
title_fullStr | Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects |
title_full_unstemmed | Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects |
title_short | Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects |
title_sort | dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes indian subjects |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603104/ https://www.ncbi.nlm.nih.gov/pubmed/23565456 http://dx.doi.org/10.4103/2230-8210.104121 |
work_keys_str_mv | AT sanyaldebmalaya dyslipidemiametabolicsyndromeandliverenzymesinimpairedglucosetoleranceandnewonsetuntreatedtype2diabetesindiansubjects AT ghoshsujoy dyslipidemiametabolicsyndromeandliverenzymesinimpairedglucosetoleranceandnewonsetuntreatedtype2diabetesindiansubjects AT mukherjeepradip dyslipidemiametabolicsyndromeandliverenzymesinimpairedglucosetoleranceandnewonsetuntreatedtype2diabetesindiansubjects AT mukherjeesatinath dyslipidemiametabolicsyndromeandliverenzymesinimpairedglucosetoleranceandnewonsetuntreatedtype2diabetesindiansubjects AT chowdhurysubhankar dyslipidemiametabolicsyndromeandliverenzymesinimpairedglucosetoleranceandnewonsetuntreatedtype2diabetesindiansubjects |